Moe Alsumidaie

Key considerations for successful implementation in decentralized clinical trials.

Strategies for sustaining clinical operations during wartime.

Valerie Powell, Vice President of Research Services at HealthiVibe, discusses her experience with obtaining patient insights and helping her clients apply them to trial design and conduct in a pandemic.

John Reites, CEO of THREAD Research, discusses how data collection is changing as the industry moves towards decentralized approaches.

A discussion of the forces currently impacting global operations, FDA foresight on operating clinical studies during COVID, and the subsequent compliance issues manifesting from poorly executed decentralized clinical trial operations.

Hassan Kadhim, Director, Global Head of Clinical Trial Business Capabilities, Clinical Innovation & Industry Collaborations at Bristol Myers Squibb, discusses his perspectives on how the pandemic has shifted clinical innovation.

With the biopharma industry making strides in gene therapies by focusing on patients with specific genetic traits, Karmen Trzupek, Director of Clinical Trial Services at InformedDNA, discusses how to address the presented challenges of this approach.

John Rigg, senior principal, Predictive Analytics, Real World Solutions at IQVIA, discusses how patient disease modeling and diagnostic prediction is made possible with artificial intelligence and machine learning.

While the clinical trials industry has always been a slacker in innovation, we'll soon start seeing automation and artificial intelligence significantly impacting the way biopharmaceutical enterprises run clinical trials, says Moe Alsumidaie.

Patrick Jordan, Chief Executive Officer of Mycovia, discusses the company's strategies on tackling Recurrent Vulvovaginal Candidiasis.

Despite mounting frustrations in drug R&D for Alzheimer's disease, emerging biophar­ma firms are still pursuing AD therapies with new science, and differ­ent preclinical and clinical trial models.

Moe Alsumidaie interviews Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics, Inc., who discusses navigating the new wave of genomic medicine.

President and CEO of Cyclacel, Spiro Rombotis, discusses why targeting cyclin-dependent kinases and the DNA repair pathway could enhance care across various oncology indications.

A leading industry executive in the regenerative medicine space discusses recent advances in stem cell therapy development.

Examining the distinct actions and advocacy that have advanced the concept from buzzword status to practical implementation in clinical studies.

Database integration initiatives in the biopharmaceutical industry is now enabling clinical development departments to leverage that data for enhancing decision-making.

Dr. Tshaka Cunningham, Associate Director of Scientific Collaboration for DIA, will discuss his perspectives on advancements in gene editing therapies and their impact on the industry.

Columnist Moe Alsumidae speaks to key Synteract executives on their acquisition of a dermatology CRO to augment its own expertise and grow the specific services necessary for this therapeutic specialty.